03.04.2018 • NewsPeopleDr. Reddy'sPharma

Erez Israeli Joins Dr. Reddy’s as New Chief Operating Officer

On Apr. 2, 2018, Erez Israeli joined Indian pharmaceutical company Dr. Reddy’s as COO and global head of Generics & PSAI. Israeli, former president & CEO of Enzymotec, succeeded Abhijit Mukherjee, who retired on Mar. 31, 2018, after 15 years with the company. In his Israely, he will report to Dr. Reddy’s co-chairman & CEO, G.V. Prasad.

Before joining Enzymotec, Israeli worked for 23 years at Teva Pharmaceuticals where he has held several leadership position.

G.V. Prasad commented on the transition: “I would like to thank Abhijit for his valuable contribution to our company’s growth journey over the past fifteen years. I extend a warm welcome to Erez Israeli. Erez is an accomplished leader with a proven track record of achievement. His knowledge and experience from leading pharmaceutical businesses of scale will be valuable for our future growth.”

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.